Thursday, Can-Fite BioPharma Ltd. (CANF) announced encouraging results from its Phase 2a clinical trial for namodenoson, a drug aimed at treating advanced pancreatic cancer.
In the study, more than 30 percent of the patients who could be evaluated had stable disease, and a few were able to stay on the treatment for quite a while; one patient even went beyond 16 months.
Right now, around 35 percent of the patients are still receiving therapy, suggesting this drug could provide lasting benefits, especially since these patients had already undergone a lot of previous treatments.
The company plans to share more detailed efficacy data, including survival rates, in the months ahead.
CANF is currently trading at $3.43, up $0.44 or 14.72 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.